Navigation Links
Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
Date:8/28/2007

SAN DIEGO, Aug. 28 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) today announced the enrollment of the first subject in its Phase 1 trial of the company's Vaxfectin(TM)-formulated plasmid DNA (pDNA) pandemic influenza vaccine. The double-blind, placebo-controlled trial will evaluate safety, tolerability and immune responses in up to 60 healthy volunteers age 18 to 45 at two U.S. clinical sites.

"We have designed a promising pandemic influenza vaccine and demonstrated its effectiveness against a highly lethal H5N1 challenge in ferrets, the best available animal model," said Vijay B. Samant, Vical's President and Chief Executive Officer, "and we have now begun testing in humans. The currently stockpiled pandemic influenza vaccines primarily generate antibody responses against a specific strain, and have a limited shelf life because they cannot be stored frozen. Our pDNA vaccine is designed to provide T-cell and antibody immune responses for broad cross-strain protection, and if frozen, would offer improved storage and deployment. This trial is also important because it marks the first time in humans for our Vaxfectin(TM) adjuvant, which has potential applications with both pDNA vaccines and conventional protein-based vaccines."

Vical's vaccine contains three individual DNA plasmids encoding consensus sequences of two highly-conserved influenza virus proteins -- nucleoprotein (NP) and ion channel protein (M2) -- plus a hemagglutinin (HA) surface protein from the H5N1 influenza virus strain, A/Vietnam/1203/04. The combination is designed to elicit both T-cell and antibody immune responses against emerging strains of influenza virus that have the potential to cause a pandemic. A monovalent pDNA va
'/>"/>

SOURCE Vical Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vaccine Can Prevent Cervical Cancer and Precancerous Lesions
2. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
3. Vical Licensee AnGes MG Announces Positive Results of Phase 3 Angiogenesis Trial in Japan
4. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
5. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
6. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
7. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
8. Cervarix, GSK Cervical Cancer Candidate Vaccine, Demonstrates 100 Percent Protection Against Precancerous Lesions Caused By Cancer-Causing Human Papillomavirus Types 16 & 18 for More Than Five Years
9. Vicals Vaxfectin Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine
10. Nventa Announces Presentation of Positive HspE7 Data from NCI-Sponsored Clinical Trial in Cervical Dysplasia
11. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... 1, 2014   Intarcia Therapeutics, Inc. today ... phase 3 clinical trials for ITCA 650 (exenatide, delivered ... osmotic mini-pump). The first trial, FREEDOM-1, was a placebo-controlled, ... and safety of ITCA 650 in patients with type ... to be significantly superior to placebo for both 40 ...
(Date:10/1/2014)... and NOTTINGHAM, England , Oct. ... CBRX ) today announced that its subsidiary, Molecular Profiles ... Trials platform at the annual CPhI/ICSE Worldwide event in ... to support companies with the rapid development of both ... enabling technologies screening platform, which incorporates the company,s existing ...
(Date:10/1/2014)... Oct. 1, 2014  Varian Medical Systems (NYSE: ... results for the fourth quarter of fiscal year 2014 ... 22, 2014.  The news release will be followed by ... p.m. PT.  The news release and a link to ... company website at: www.varian.com/investor .  To access the ...
Breaking Medicine Technology:Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 2Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 5Columbia Laboratories' UK Subsidiary To Launch New Development Platform At CPHI 2Columbia Laboratories' UK Subsidiary To Launch New Development Platform At CPHI 3Varian Medical Systems Schedules Fourth Quarter FY2014 News Release and Conference Call 2
... FLEX ) is expanding its medical disposables offering ... through a share purchase agreement. Slomedical is a leading ... sets to complex devices for minimally-invasive surgery. This deal ... calendar year, pending required regulatory clearances. , Upon ...
... , CLINTON, N.J., Oct. 21 Ikaria Holdings, Inc. ... Award for Excellence in Business Expansion by the New ... employer association in the United States. Ikaria earned ... revenues, as well as the net creation of new ...
Cached Medicine Technology:Flextronics Announces Expansion of Medical Disposables Offering 2Ikaria Receives Award for Excellence by New Jersey Business & Industry Association 2
(Date:10/2/2014)... 2014 Recently, BambooIndustry.com, a professional company ... collection of bamboo floors . What’s more, the ... of its products at the moment. According to the ... 26 percent off. The promotion will be valid until ... http://www.bambooindustry.com ) are all made by qualified workers. A ...
(Date:10/2/2014)... BamboofloorChina.com is a distinguished bamboo product manufacturer ... appreciation from the global customers in the past few ... more excellent items. All its online workers are professional ... , The company has recently added a new ... Furthermore, the company’s marketing specialist has announced that all ...
(Date:10/2/2014)... Children with autism are more sedentary than those without ... active, a small study suggests. Researchers tested the ... autism and some without. Children with autism averaged 50 ... 70 more minutes each day sitting than those without ... on strength, but had similar body-mass index (a measurement ...
(Date:10/2/2014)... Dennis Thompson HealthDay Reporter ... the District of Columbia now have a total of 500 ... has been infecting children since the summer, U.S. health ... have died in recent weeks, but it,s not clear what ... deaths, officials said. Health officials are also trying to ...
(Date:10/1/2014)... new research study published today in the Journal ... patients older than 50 years with moderate or severe ... , Researchers from the University of Melbourne randomly assigned ... pain to no acupuncture or sham or pretend laser ... with participants and acupuncturists blinded to laser and sham ...
Breaking Medicine News(10 mins):Health News:BambooIndustry.com: Great Bamboo Floors At Discounted Rates 2Health News:High Quality Bamboo Panels Online At BamboofloorChina.com 2Health News:Kids With Autism Tend to Be Less Active, Study Says 2Health News:42 States Reporting Respiratory Virus That Targets Kids 2Health News:42 States Reporting Respiratory Virus That Targets Kids 3Health News:Study finds acupuncture does not improve chronic knee pain 2
... method cuts death risk, study finds , WEDNESDAY, Aug. ... who receive early non-invasive ventilation after a breathing tube ... failure or die, a Spanish study has found. , ... of them had high levels of carbon dioxide in ...
... behind progress, study finds , THURSDAY, Aug. 13 (HealthDay ... younger people, new research shows. , And while cancer ... the United States, topping heart disease, that is because ... cancer. , "Older Americans have only experienced decreased [cancer] ...
... YORK, Aug. 13 The International Longevity Center, with support ... $20,000 grants for caregiver training programs. , , ... Initiative grants are part of the Caregiving Project for ... the Schmieding Center for Senior Health and Education. The initiative ...
... , , BALTIMORE, Aug. ... Maryland, the Black Nurses Association of Baltimore and the Greater ... Health Insurer Code of Conduct from the American Medical Association. ... portion of the state,s racial and ethnic minorities, including African ...
... , THOUSAND OAKS, Calif., Aug. 13 ... data from the submitted Biologic License Applications (BLAs) for denosumab for ... treatment of bone loss in breast and prostate cancer patients undergoing ... Administration,s (FDA) Advisory Committee for Reproductive Health Drugs (ACRHD). , ...
... RICHMOND, Va., Aug. 13 Insmed Inc. (Nasdaq: ... second quarter and six-months ended June 30, 2009. , , ... were $3.0 million, up from $2.7 million for the corresponding period ... grant revenue related to the IPLEX(TM) myotonic muscular dystrophy ("MMD") clinical ...
Cached Medicine News:Health News:Ventilation After Breathing Tube Removal May Alter Outcomes 2Health News:Cancer Deaths Declining, Especially Among Young 2Health News:Cancer Deaths Declining, Especially Among Young 3Health News:Fifteen Community Colleges Win Awards for Innovative Caregiving Training Programs 2Health News:Fifteen Community Colleges Win Awards for Innovative Caregiving Training Programs 3Health News:Fifteen Community Colleges Win Awards for Innovative Caregiving Training Programs 4Health News:Fifteen Community Colleges Win Awards for Innovative Caregiving Training Programs 5Health News:Leading African American Groups Call On Health Insurers to Dismiss Restrictive Practices 2Health News:Leading African American Groups Call On Health Insurers to Dismiss Restrictive Practices 3Health News:Amgen to Discuss Denosumab Data at Today's Advisory Committee for Reproductive Health Drugs 2Health News:Amgen to Discuss Denosumab Data at Today's Advisory Committee for Reproductive Health Drugs 3Health News:Amgen to Discuss Denosumab Data at Today's Advisory Committee for Reproductive Health Drugs 4Health News:Amgen to Discuss Denosumab Data at Today's Advisory Committee for Reproductive Health Drugs 5Health News:Amgen to Discuss Denosumab Data at Today's Advisory Committee for Reproductive Health Drugs 6Health News:Amgen to Discuss Denosumab Data at Today's Advisory Committee for Reproductive Health Drugs 7Health News:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009 2Health News:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009 3Health News:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009 4Health News:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009 5Health News:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009 6Health News:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009 7Health News:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009 8Health News:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009 9
.90mm (20G) guillotine cutting probe with 1.4mm (17G) removable irrigation sleeve...
Cannula: .90mm x 28mm (20 G x 1 1/8 in) Handle: 9.3cm (3 5/8 in) long, Flute, .90 x 28mm, vacuum handle [Charles]...
...
Designed for stab incisions...
Medicine Products: